Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

Annals of the Rheumatic Diseases

Volumn 72, Issue 2, 2013, Pages 229-234

  Galloway, James B ^a   Mercer, Louise K ^a   Moseley, Alison ^a,b   Dixon, William G ^a   Ustianowski, Andrew P ^c   Helbert, Matthew ^d   Watson, Kath D ^a   Lunt, Mark ^a   Hyrich, Kimme L ^a   Symmons, Deborah P M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE REGISTRY; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SKIN INFECTION; SOFT TISSUE INFECTION; SURVIVAL; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HERPES ZOSTER; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872056023     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201108     Document Type: Article

References (18)

1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
2. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31.
3. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
4. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
5. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
6. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
7. García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-5.
8. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23.
9. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
10. Hyrich KL, Watson KD, Isenberg DA, et al. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 2008;47:1441-3.
11. National Institute for Health and Clinical Excellence. Guidance on the use of etanercept and infliximab for rheumatoid arthritis. London, UK: NICE, 2002.
12. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
13. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
14. Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 2007;45(10 Suppl 2):S103-7.
15. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
16. Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster. MMWR Morb Mortal Wkly Rep 2008;50:1-30.
17. Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011;13:R174.
18. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138-44.